Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00318838 · ClinicalTrials.gov registry record · Phase 1
Effect of Azimilide Dihydrochloride on Renal Function
A Phase 1 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT00318838 is a Phase 1 study that has completed, run by Forest Laboratories. The registered enrollment target is 21 participants.
The verdict
NCT00318838, a Phase 1 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This study will assess the effect of multiple dosing of 125 mg azimilide on glomerular filtration rate (GFR) and total creatinine clearance (GFR + active secretion) in healthy subjects. Also, it will assess the effect of multiple dosing of 125 mg azimilide on renal hemodynamics (RPF) in healthy subjects.
Interventions
- DRUG Placebo
- DRUG Azimilide dihydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2006-04 |
| Est. Completion | 2006-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00318838
The ClinicalTrials.gov registry entry for NCT00318838 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00318838 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00318838 about?
NCT00318838 is a clinical study titled "Effect of Azimilide Dihydrochloride on Renal Function". This study will assess the effect of multiple dosing of 125 mg azimilide on glomerular filtration rate (GFR) and total creatinine clearance (GFR + active secretion) in healthy subjects. Also, it will assess the effect of multiple dosing of 125 mg azimilide on renal hemodynamics (RPF) in healthy subj...
What is the current status of trial NCT00318838?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2006-04. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00318838?
The interventions under investigation include: Placebo (DRUG), Azimilide dihydrochloride (DRUG).
Who is sponsoring clinical trial NCT00318838?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.